tiprankstipranks
Trending News
More News >
Britannia Life Sciences Inc (TSE:BLAB)
:BLAB

Britannia Life Sciences Inc (BLAB) AI Stock Analysis

Compare
1 Followers

Top Page

TS

Britannia Life Sciences Inc

(BLAB)

Rating:42Neutral
Price Target:
Britannia Life Sciences displays significant financial challenges with high leverage and inconsistent revenue, negatively impacting its stock score. The technical analysis indicates weak momentum, and valuation metrics are poor. However, the recent strategic sale of a subsidiary provides a slight positive outlook, contributing to a modest score improvement.

Britannia Life Sciences Inc (BLAB) vs. iShares MSCI Canada ETF (EWC)

Britannia Life Sciences Inc Business Overview & Revenue Model

Company DescriptionBritannia Life Sciences Inc (BLAB) is a company engaged in providing a comprehensive suite of services to the cosmetic, nutraceutical, and consumer goods sectors. The company specializes in product formulation, quality assurance, regulatory compliance, and consumer testing. By leveraging its expertise, Britannia Life Sciences supports businesses in bringing innovative products to market efficiently and in compliance with industry standards.
How the Company Makes MoneyBritannia Life Sciences Inc generates its revenue through a variety of service-based offerings tailored to the needs of the cosmetic, nutraceutical, and consumer goods industries. The company earns income by providing product formulation services, which involve creating and testing new product formulations for clients. Additionally, it offers quality assurance and regulatory compliance services, ensuring that products meet necessary legal and safety standards before they reach the market. Consumer testing services also contribute to revenue by providing insights into product performance and consumer preferences. Partnerships with industry players and a focus on delivering comprehensive solutions further enhance Britannia Life Sciences' revenue streams.

Britannia Life Sciences Inc Financial Statement Overview

Summary
Britannia Life Sciences Inc. faces significant financial challenges. The income statement reflects operational inefficiencies with negative EBIT and EBITDA, and inconsistent revenue growth. The balance sheet highlights high leverage with low equity, posing financial risks. Cash flow shows some positive operating cash flow but remains volatile due to underlying profitability issues.
Income Statement
40
Negative
The company's income statement reveals significant challenges. The TTM data shows a decrease in revenue and a negative EBIT and EBITDA, indicating operational inefficiencies. Net income is also negative, reflecting poor profitability. The gross profit margin is relatively stable but not enough to offset the high operational costs. Revenue growth over the past year has been inconsistent, with a decline from the previous year, indicating market or operational challenges.
Balance Sheet
30
Negative
The balance sheet highlights financial instability with a high debt-to-equity ratio and low equity. The company's equity is minimal compared to its liabilities, posing financial risk. Return on equity is negative due to sustained net losses. The equity ratio is low, indicating potential solvency issues. Overall, the balance sheet suggests the company is highly leveraged, with significant financial risks.
Cash Flow
45
Neutral
The cash flow statement shows some positive aspects, such as positive operating cash flow in the TTM period, which indicates some ability to generate cash from operations. However, the free cash flow growth rate is volatile, and the free cash flow to net income ratio is unstable due to negative net income. The company has managed to reduce capital expenditures, which helps improve free cash flow, but cash flow challenges remain due to underlying profitability issues.
Breakdown
TTMMar 2024Mar 2023Mar 2022Mar 2021Mar 2020
Income StatementTotal Revenue
7.19M7.57M6.40M7.30M1.42M974.27K
Gross Profit
4.09M4.85M4.64M5.26M1.17M285.38K
EBIT
-5.06M173.00K177.74K379.57K114.83K-5.20M
EBITDA
-5.09M-1.90M6.95M-10.77M-1.62M-5.35M
Net Income Common Stockholders
-7.98M-4.77M5.08M-15.46M-157.16K-7.13M
Balance SheetCash, Cash Equivalents and Short-Term Investments
1.32M1.32M2.60M1.63M828.32K2.18M
Total Assets
22.26M22.26M23.55M21.09M21.45M3.16M
Total Debt
7.04M7.29M8.41M5.19M10.55M9.34M
Net Debt
5.71M5.96M5.81M3.56M9.72M7.16M
Total Liabilities
15.59M15.59M12.49M15.61M18.79M13.24M
Stockholders Equity
2.44M2.44M7.02M1.35M-202.32K-10.08M
Cash FlowFree Cash Flow
654.30K1.75M874.41K2.71M-543.49K-5.25M
Operating Cash Flow
1.11M2.09M1.22M2.80M-586.58K-5.18M
Investing Cash Flow
-460.06K-1.44M-3.32M653.95K-4.91M-68.38K
Financing Cash Flow
-1.46M-1.97M2.95M-2.58M6.20M3.55M

Britannia Life Sciences Inc Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.06
Price Trends
50DMA
0.07
Negative
100DMA
0.07
Negative
200DMA
0.06
Negative
Market Momentum
MACD
>-0.01
Positive
RSI
41.42
Neutral
STOCH
<0.01
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:BLAB, the sentiment is Negative. The current price of 0.06 is below the 20-day moving average (MA) of 0.07, below the 50-day MA of 0.07, and below the 200-day MA of 0.06, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 41.42 is Neutral, neither overbought nor oversold. The STOCH value of <0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:BLAB.

Britannia Life Sciences Inc Peers Comparison

Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
54
Neutral
$5.31B3.28-45.10%2.80%16.76%0.02%
TSKNE
43
Neutral
C$8.29M-813.02%
42
Neutral
C$9.74M-175.45%-3.93%-575.24%
29
Underperform
$11.66M
48.63%
21
Underperform
C$12.37M26.73%-62.39%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
TSE:BLAB
Britannia Life Sciences Inc
0.06
0.00
0.00%
TSE:BETR
BetterLife Pharma
0.09
-0.03
-29.17%
TSE:BIOV
BioVaxys Technology
0.04
-0.03
-42.86%
TSE:KNE
Kane Biotech
0.05
-0.08
-61.54%

Britannia Life Sciences Inc Corporate Events

M&A TransactionsBusiness Operations and Strategy
Britannia Life Sciences Strengthens Financial Position with Strategic Sale
Positive
Jan 28, 2025

Britannia Life Sciences Inc. has completed the sale of its UK operating subsidiary, Advanced Development and Safety Laboratories Inc., resulting in net proceeds of approximately $13 million. The company is prioritizing strategic capital allocation to optimize shareholder returns and support sustainable growth. Britannia is also focusing on its investment in Britannia Mining Solutions, recognizing its potential to drive value and align with the company’s strategic goals.

Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.